HRA’s Efficient Ella Development Strategy Begat FDA’s Efficient NDA Review

The story of HRA Pharma’s emergency contraceptive Ella (ulipristal) bears many of the hallmarks of what many sponsors would consider a desirable regulatory path, culminating in a first-cycle approval with clean labeling.